Can Aqualase replace phaco?

Article

Removal of soft cataracts with Aqualase (Alcon), theoretically carries less risk to the posterior capsule than phacoemulsification.

Removal of soft cataracts with Aqualase (Alcon), theoretically carries less risk to the posterior capsule than phacoemulsification, according to a report published in the February issue of Eye.

Laurence Whitefield and colleagues from Queen Mary's Hospital, Kent, UK, enrolled 33 subjects (mean age 71.4 years) to undergo cataract surgery using Aqualase through a 3.2 mm corneal incision. Grade of nucleus, nuclear removal technique and intraoperative complications were recorded.

The researchers found that Aqualase is capable of removing cataracts up to nuclear sclerosis 2+ fairly easily. Nuclei that were graded 2+ or greater were more technically difficult and conversion to ultrasound phacoemulsification was required in one case. Of the 33 procedures there were just two cases of posterior capsule rupture. One occurred during nucleus removal and the other was unrelated to Aqualase. A total of 96% of the subjects, without preoperative comorbidity, achieved 6/9 or better postoperatively.

The researchers feel that Aqualase does have an advantage over phacoemulsification, as it carries less risk of damage to the posterior capsule. Additionally, the method is similar enough to phacoemulsification to ensure that the learning curve is not too steep. However, they emphasize that Aqualase it is not completely risk free as rupture is possible with the floor pedal in position two.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.